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Abstract
Background: Ganciclovir is a therapeutic choice for extremely premature infants with severe postnatal
cytomegalovirus disease, but little is known about its optimal dose size and dosing interval for them.
Case presentation: We treated an extremely premature female infant with postnatal cytomegalovirus infection
with intravenous administration of ganciclovir since 49 days of life (postmenstrual age of 31 weeks). After ganciclovir
treatment was initiated at a dose of 5 mg/kg every 12 h, cytomegalovirus loads in the peripheral blood were markedly
decreased. However, since plasma ganciclovir trough level was too high, the interval was extended to every 24 h.
Subsequently, the trough level and the estimated 12-h area under the concentration–time curve (AUC0–12) were
decreased from 3.5 mg/L to 0.3 mg/L and 53.9 mg · h/L to 19.2 mg · h/L, respectively, resulting in an exacerbation of
viremia and clinical condition. Adjustment of dosing interval from 24 h to 12 h led to a peak level of 4.2 mg/L, trough
level of 1.1 mg/L, and AUC0–12 of 31.8 mg · h/L, resulting in a marked suppression of viral load.
Conclusions: Monitoring the therapeutic drug levels and cytomegalovirus loads is useful in obtaining a proper
treatment effect and preventing overdosage during ganciclovir therapy in premature infants with postnatal
cytomegalovirus infection.
Keywords: Ganciclovir, Postnatal cytomegalovirus infection, Therapeutic drug monitoring, Extremely low birth
weight infant
Abbreviations: AUC, Area under the concentration–time curve; CMV, Cytomegalovirus; PCR, Polymerase chain
reaction; TDM, Therapeutic drug monitoring; VL, Viral load
Background
Postnatal cytomegalovirus (CMV) infection, largely
acquired via breastmilk, is usually asymptomatic in full-
term infants. However, extremely premature infants
appear to have a higher risk of developing symptomatic
postnatal CMV infection, characterized by hepatitis,
neutropenia, thrombocytopenia, respiratory failure, and
sepsis-like syndrome [1, 2].
Although ganciclovir is an anti-CMV drug that has
been shown to be effective against severe CMV diseases,
little is known about its optimal dose size and dosing
interval for extremely premature infants [3].
We have recently experienced a case of an extremely
premature infant with severe postnatal CMV infection.
During the treatment with ganciclovir, we performed
therapeutic drug monitoring (TDM) and measurement
of CMV load in the peripheral blood that were useful to
obtain a proper therapeutic effect and avoid overdosage.
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Case presentation
A 37-year-old primigravid woman was referred to the
emergency department due to premature ablation of a
normally implanted placenta. After admission, an
extremely low birth weight female infant (birth weight,
532 g; length, 27 cm) was delivered by Cesarean section
at 24 + 0 weeks of gestation. Her Apgar scores at 1, 5,
and 10 min were 1, 3, and 7, respectively. The umbilical
artery pH was 6.91. She was intubated shortly after birth
due to respiratory distress, and surfactant was adminis-
tered. The surgical ligation of a patent ductus arteriosus
was performed at 15 days of life. She began receiving
hydrocortisone from 16 days of life because of respira-
tory deterioration. Enteral feeding with fresh breast milk
was started on 2 days of life, and the infant was on full
feeding by 28 days of life.
A cystic lesion had been identified below the liver dur-
ing the fetal period, and we diagnosed biliary atresia
after her birth. On 34 days of life, cholestatic jaundice
developed (direct bilirubin 16.9 mg/dL), and a biliary
drainage procedure was performed.
On 43 days of life, she developed progressive abdominal
distension and a septic appearance. Laboratory values
showed thrombocytopenia (41 × 103/μL) and elevation of
C-reactive protein levels (16.2 mg/dL). Empiric antibiotic
therapy, using vancomycin and meropenem, and intraven-
ous immunoglobulin therapy were started for clinically
suspected sepsis. Serial blood cultures were negative for
both aerobic and anaerobic bacterial infections.
In view of thrombocytopenia and necrotizing
enterocolitis-like ileus, we performed a CMV screening
at the same time. Her urine was positive for CMV
DNA, and real-time polymerase chain reaction (PCR)
showed a VL of 5.0 × 106 copies/mL in the peripheral
blood. The CMV DNA from the umbilical cord and
Guthrie card, both of which were collected on 16 days
of life, were below the limits of detection. Real-time
PCR of her mother’s breast milk showed a CMV load
of 3.9 × 104 copies/mL. Although she had received five
red packed cell transfusions by 43 days of life, they
were all irradiated and leucocyte-depleted. Those re-
sults suggested that the breast milk was the most likely
source of virus transmission to the patient.
As the thrombocytopenia and necrotizing enterocolitis-
like ileus further deteriorated, we decided to begin
antiviral therapy with intravenous ganciclovir. Ganciclovir
therapy (5 mg/kg per dose every 12 h) was initiated at
49 days of life (postmenstrual age of 31 weeks).
We performed the TDM for ganciclovir three times,
using liquid chromatography-tandem mass spectrometry.
The estimated 12-h area under the concentration–time
curve (AUC0–12) was determined using the trapezoidal
method. When the drug interval was 24 h, the estimated
AUC0–12 was corrected for half of the calculated value
using the trapezoidal method. Table 1 shows the associ-
ation between the CMV load and the ganciclovir TDM
analysis. At 55 days of life (7th treatment day), we per-
formed the first ganciclovir TDM analysis. The plasma
ganciclovir levels at 30 min, 90 min, 6 h, and 11 h after
ganciclovir infusion were 5.3 mg/L, 6.0 mg/L, 4.0 mg/L,
and 3.5 mg/L, respectively; the estimated AUC0–12 was
53.9 mg · h/L. The CMV load decreased from 5.0 × 106 to
5.3 × 104 copies/mL in parallel with the increase of platelet
counts. The ganciclovir trough level and the estimated
AUC0–12 were too high, so we extended the dosing inter-
val from 12 h to 24 h on 62 days of life (14th treatment
day). On 70 days of life (22nd treatment day), we per-
formed the second TDM analysis, demonstrating that the
plasma peak and trough ganciclovir levels were 6.0 mg/L
and 0.3 mg/L, respectively, and the estimated AUC0–12
was 19.2 mg · h/L. Concurrently, the CMV load modestly
rebounded from 5.3 × 104 to 1.6 × 105 copies/mL, and the
thrombocytopenia worsened (35 × 103/μL). Therefore, we
shortened the dosing interval from 24 h to 12 h on 29th
treatment day. On 84 days of life (36th treatment day), we
performed the third TDM analysis, demonstrating that
the plasma peak and trough ganciclovir levels were
4.2 mg/L and 1.1 mg/L, respectively, and the estimated
AUC0–12 was 31.8 mg · h/L. Although the VL markedly de-
creased from 1.6 × 105 to 2.4 × 103 copies/m/L, her clinical
condition deteriorated with thrombocytopenia, hepatitis
(aspartate transaminase: 422 IU/L; alanine transaminase:
87 IU/L), and unconjugated hyperbilirubinemia (serum
direct bilirubin: 10.3 mg/dL). Neither neutropenia nor
renal impairment was observed during ganciclovir ther-
apy. On 85 days of life (37th treatment day), the ganciclo-
vir therapy was discontinued, because of the concern that
the thrombocytopenia and hepatitis resulted from its
adverse reactions. Her clinical condition further deterio-
rated with increase of VL to 1.0 × 106 copies/mL on
107 days of life. On 109 days of life, she died of hepatic
failure. Extensive hepatocyte necrosis was noted at
necropsy and on histopathological examination; however,
the precise mechanism of liver injury was not revealed by
the postmortem analyses. This infant’s clinical course is
summarized in the accompanying supplemental time-line
file (Additional file 1).
Conclusions
To our knowledge, this was the first description of an
extremely premature infant with postnatal CMV infec-
tion who had multiple ganciclovir TDM and CMV load
analyses. No controlled study has yet evaluated the
impact of antiviral treatment on the outcome of postna-
tal CMV infection, and there have been no treatment
recommendations yet [3]. In the present case, we
adjusted the dosing interval according to the results of
the ganciclovir TDM and CMV load. Ganciclovir was
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effective in the reduction of the CMV load in parallel
with temporal improvement of her clinical condition,
but unfortunately, our patient died.
There have been very few TDM data of ganciclovir ther-
apy in extremely premature infants [4]. The response to
therapy with ganciclovir has been influenced by the inter-
individual pharmacokinetic variability. Thus, low plasma
levels of ganciclovir are associated with therapy failure and
also predispose the virus to drug resistance, although
optimal therapeutic drug levels have not been well estab-
lished [4]. Plasma ganciclovir trough levels below 0.6 mg/L
are associated with therapy failure during the intravenous
ganciclovir administration for CMV retinitis [5]. Based on
existing data and concerns regarding under-treatment, a
trough level of 0.5–1.0 mg/L may be optimal [4]. In our
patients, we started ganciclovir therapy at 5 mg/kg per
dose every 12 h. The ganciclovir peak level sufficiently
increased; therefore, a ganciclovir dose of 5 mg/kg per dose
appeared to be optimal. In contrast, the trough levels
varied with the drug interval, her age, and her condition,
making it difficult to set up the optimal treatment plan.
Side effects of ganciclovir include neutropenia, hearing
loss, bone marrow suppression, raised liver enzymes,
hypokalemia, and renal impairment [6, 7]. In a previous
pharmacokinetic study of the use of intravenous ganciclo-
vir in infants with symptomatic congenital cytomegalo-
virus, the target AUC0–12 was defined as 27 m · h/L to
avoid side effects [8]. In our case, thrombocytopenia wors-
ened upon ganciclovir therapy; however, it was not due to
ganciclovir, but probably because of hepatocirrhosis with
biliary atresia. There was no evidence of other side effects,
including neutropenia and renal impairment. Apparent
lack of side effects may be due to the fact that we per-
formed the ganciclovir TDM analyses and avoided high
AUC accordingly.
We believe that ganciclovir therapy can bring about
both virological improvement and clinical benefits,
and propose that it should be a therapeutic option
for severe postnatal CMV infection in extremely
premature infants. The present case had such compli-
cating and serious clinical conditions as extreme
prematurity and hepatobiliary dysfunction. Ganciclovir
is excreted largely unchanged by the kidneys and
hepatic metabolism of the drug is only minimal.
Therefore, it is quite likely that pharmacokinetics of
ganciclovir was influenced by renal insufficiency and
characteristic body fluid composition accompanied by
prematurity. While direct influence of hepatobiliary
disorder on drug metabolism is unlikely, severe liver
failure can cause secondary renal dysfunction, which
might influence pharmacokinetics of the drug in this
patient. In this regard, we believe TDM is needed in
any complicating and serious clinical condition. It is
important, therefore, to analyze the ganciclovir TDM
and CMV load to secure the efficacy and safety of
ganciclovir therapy in extremely premature infants.
Since there have been only limited data regarding the
pharmacokinetics, safety profiles, and adverse effects
of ganciclovir in infants, especially extremely prema-
ture infants [9], further studies are warranted to
establish antiviral treatment for them.
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48 30 + 6 1132 0.39 Reference (pre-therapy) 5.0 × 106
55 31 + 6 1296 0.32 5 12 6.0 3.5 53.9 5.3 × 104
70 34 + 0 1120 0.26 5 24 6.0 0.3 19.2 1.6 × 105
84 36 + 0 1326 0.27 5 12 4.2 1.1 31.8 2.4 × 103
107 39 + 2 2058 0.32 22 days post-therapy 1.0 × 106
CMV cytomegalovirus, TDM therapeutic drug monitoring, AUC area under the concentration-time curve
aThe peak levels of ganciclovir were measured at 90 min after ganciclovir infusion
bThe trough levels of ganciclovir were measured at 11 h after ganciclovir infusion
cThe estimated values of AUC0–12 were calculated using Trapezoidal rule
dCMV loads in the peripheral blood were determined by real-time PCR
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